<DOC>
	<DOCNO>NCT00073021</DOCNO>
	<brief_summary>This study prospective clinical study evaluate safety efficacy two different dos Asacol treatment moderately active ulcerative colitis . In addition , new tablet formulation evaluate one two dos .</brief_summary>
	<brief_title>Safety Efficacy Two Different Doses Asacol Treatment Moderately Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>male female 18 75 year age ; confirm diagnosis ulcerative colitis extent vary proctitis pancolitis ; currently demonstrate moderately active disease Patients exclude admission study have/are : history allergy hypersensitivity salicylates aminosalicylates ; history extensive small bowel resection ( &gt; 1/2 length small intestine ) cause short bowel syndrome ; current renal hepatic disease ; participate drug device clinical study within 30 day entry ; currently enrol clinical study ; receive oral , intravenous , intramuscular , rectally administer corticosteroid within 1 month prior Baseline Visit ; receive topical rectal therapy week prior Screening Visit ; receive immunomodulatory therapy include , limited , 6mercaptopurine , azathioprine , cyclosporine , methotrexate within 3 month prior Baseline Visit ; receive dose mesalaminecontaining compound route 1.6 g/day mesalamine available within 1 week prior Screening Visit ( NOTE : 4 g/day sulfasalazine 4.5 g/day balsalazide equivalent 1.6 g/day mesalamine ) ; receive antibiotic , topical antibiotic , within 1 week prior Screening Visit ; receive aspirin ( except cardioprotective reason maximum dose 325 mg/day ) NSAIDs within 1 week prior Baseline Visit ; female , positive pregnancy test , lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>